Myo-Inositol for Ovulation Support

Myo-inositol is the best-supported non-prescription option for restoring ovulation in polycystic ovary syndrome, and that qualifier matters — most of the evidence sits in PCOS, where anovulation is driven by insulin resistance rather than in ovulatory cycles generally. In women with PCOS, trials consistently report more ovulatory cycles, shorter and more regular cycle length, and improvements in the insulin and androgen picture that sits underneath the problem. What the evidence does not yet show clearly is a reliable improvement in live birth rate. Meta-analyses find better ovulation and cycle frequency, but rate the pregnancy and live birth data as insufficient. That gap is the honest headline: myo-inositol appears to fix an intermediate step well, and whether that reliably carries through to a baby has not been demonstrated at the standard we would want. It is well tolerated, inexpensive relative to fertility treatment, and slow — expect three to six months, not three weeks.

Myo-inositol is a sugar alcohol that acts as the backbone of inositol phosphoglycan second messengers, which sit downstream of the insulin receptor. In PCOS, a defect in converting myo-inositol to its isomer D-chiro-inositol in the ovary appears to leave ovarian tissue relatively myo-inositol depleted, while systemic insulin resistance persists. Supplementation restores substrate for that signalling. The consequence at the ovary is improved FSH signalling and better oocyte quality, and systemically, lower fasting insulin. Lower insulin reduces ovarian androgen production and raises sex hormone binding globulin, so free testosterone falls. Less androgen excess allows follicles to progress past the arrest point that produces the classic polycystic appearance rather than a dominant follicle. This is why the effect is not immediate. You are correcting a metabolic and hormonal environment over cycles, not triggering an ovulation event.

The strongest single piece of evidence is a 2018 BJOG meta-analysis of randomised trials in anovulatory PCOS, which found inositol improved ovulation rate and cycle frequency against placebo, and produced metabolic improvements broadly comparable to metformin. Its stated conclusion on the outcomes that matter most — clinical pregnancy and live birth — was that evidence remains insufficient, chiefly because the trials were small and rarely followed women to delivery. A 2017 meta-analysis in Endocrine Connections reinforced the metabolic story, reporting significant reductions in fasting insulin and HOMA index and improved androgen profiles, with less consistent effects on reproductive endpoints. Earlier work in Gynecological Endocrinology reported that 4 g/day with folic acid restored spontaneous ovulation in a substantial share of women, with clomiphene adding further benefit. Read together, the pattern is coherent: a reliable metabolic and ovulatory effect, an unproven fertility outcome, and a consistently benign safety profile. That combination justifies a trial in PCOS, not a promise.

Myo-inositol has an unusually clean tolerability record. At 4 g/day, adverse effects in trials were similar to placebo, with mild nausea, gas or loose stools the main complaints and generally only at higher intakes. It is a naturally occurring compound found in fruit, beans and grains, and the body itself synthesises several grams daily. The practical cautions are contextual rather than toxicological. If ovulation returns, fertility returns — which is the point, but it means contraception needs rethinking if pregnancy is not currently wanted. Anyone on metformin or insulin should tell their prescriber, since improving insulin sensitivity can shift dose requirements. And restoring ovulation does not investigate why cycles stopped, so an unexplored absence of periods still deserves a proper workup.